expression that decays over time. We hypothesize that the introduced vector sequences in nondividing cells perGene therapy can be defined simply as the delivery of specific nucleic acid sequences to host cells, which results sist, but assume a conformation that inactivates transcription. This may be analogous to the latent stage of the in a clinically relevant phenotypic change. The promise of this technology is that mechanisms of disease can be HSV-1 life cycle, in which the viral genome becomes methylated and histone-bound, and gene expression is altered at a more fundamental level than conventional forms of treatment, leading to new and more effective essentially quiescent. Therefore, long-term transgene expression may be critically related to the physical state interventions. Successful gene therapy is dependent on several steps, including targeting to the desired tissue, of the vector sequences, particularly in respect to access of the introduced regulatory regions to the transcriptional efficient transduction of cells, and maintenance of transgene expression for a period of time that is clinically sigmachinery of the cell.
A new generation of gene delivery vectors has been nificant. The most efficient vehicles for gene delivery are vector systems based on animal viruses. These vectors introduced which is designed to control the fate of delivered transgenes within the nucleus of transduced are designed to utilize specific biological properties of viruses, such as cell receptors for entry, that have evolved cells. Specific viral elements have been incorporated which maintain the input DNA in a physical state that over time in relationship with the host. Furthermore, viral genetics are relatively simple, well characterized can support expression and replication. This has been achieved by adding elements that either direct inteand easily manipulated; features that facilitate the design of vectors with predictable biological properties. Several gration into the host genome, or allow the vector to replicate autonomously as an episomal element within cells. different viruses have been used as the basis for gene delivery vectors, but the success of these systems is the These vectors use elements from different viruses that specify the physical state of the introduced vector product of two broad goals: maintaining the biological advantages of viruses that have been selected by nature, sequences and have been termed 'hybrid' vectors. Hybrid vectors are intended to combine advantageous properties while reducing viral determinants of cytopathic effect.
A major hurdle in gene therapy is stable transgene of current vector systems including broad host ranges, large transgene capacity and high titers, with heterologexpression. Long-term transgene expression is important because repeated administration augments the host ous elements that confer genetic stability to the vector DNA for long periods. Specific vectors are described in immune response, which leads to inhibition of gene delivery, modulation of gene expression and immuno- Table 1 . The lentiviral vectors have become the prototype for pathology. Furthermore, the physical introduction of vectors can be invasive and contribute to cytopathic effect. delivery systems that specify the cellular fate of transgenes. 1 Unlike other retroviruses, human immunodefiAfter successful delivery has occurred, expression of the introduced transgene can be further diminished by ciency virus type 1 (HIV-1) efficiently targets to the nucleus of infected cells and encodes a viral integrase promoter inactivation, physical loss or degradation of vector sequences, cytotoxic effect of the vector on the host that inserts a provirus copy into the genome of nondividing cells. HIV-1, however, has a limited host range, low cell and immune response to viral and transgene products. Current strategies for attaining vector-driven longtiters, and determinants of pathogenesis that limit its utility as a vector system. These problems have been circumterm expression include the introduction of promoter or enhancer elements that control stable, cell-or tissue-spevented by retaining advantageous elements of HIV-1, reducing the viral determinants of pathogenesis, and subcific expression. However, the fundamental goal of stable transduction is likely to be dependent on the maintestituting the HIV envelope proteins with the vesicular stomatitis virus (VSV) G surface glycoprotein. The vector nance of the introduced vector sequences in a physical state that can support long-term gene expression. Vectors is produced using a three plasmid cotransfection protocol: (1) an HIV-1 packaging plasmid; (2) a vector plasmid that exist as nonreplicating extrachromosomal elements in the nucleus of transduced cells, such as those derived containing the HIV-1 packaging signal and viral integrase, with a CMV promoter-driven transgene; and (3) a from herpes simplex virus type 1 (HSV-1) and adenovirus (Ad), do not support long-term expression. If the plasmid that expresses the VSV G surface glycoprotein. Important features of the HIV-1 parent virus are retained, target tissue is composed of dividing cells, these vectors vector, when packaged in the helper virus-free system, shows minimal cytopathic effect in culture and in vivo, We have constructed an HSV-1 based hybrid amplicon that combines desirable features of both the parent virus and constitutes a 'virtual' synthetic vector in which delivery of the transgene is mediated by HSV-1 virions in the and adeno-associated virus (AAV). Amplicon vectors are shuttle plasmids that contain the HSV-1 elements necesabsence of HSV-1 genes. A hybrid vector of similar rationale was constructed by sary for both viral DNA replication and packaging into virions. Amplicons containing one or more genes of interinserting an AAV ITR flanked marker gene into a parent adenovirus (Ad5) deleted in the E1a and E1b genes. The est can be packaged into HSV-1 virions either by replication defective HSV-1 helper virus 4 or by the recently Ad/AAV hybrid vector did not include the AAV rep gene due to its inhibitory effect on the replication of adendescribed helper virus-free method. 5 This vector has been modified by the addition of the AAV rep gene and the ovirus. Instead, a plasmid expressing the AAV Rep isoforms was conjugated to the virion surface by a poly-l-AAV inverted terminal repeats (ITRs). AAV ITRs are cisacting elements that in the presence of AAV Rep mediate lysine bridge, thereby bringing in the AAV rep gene as an extraviral component. 8 The Ad/AAV hybrid vector both amplification and subsequent integration of a desired gene into a specific site (AAVS1) in the human supports transgene amplification, as demonstrated by AAV packaging, but this system has not yet been characgenome on chromosome 19q13.3. 6 The HSV/AAV hybrid vector is designed to utilize the HSV-1 properties of entry terized for its ability to direct transgene integration or long-term gene expression. and nuclear localization, and the AAV properties of transgene amplification and integration into a nonessenLentivirus vectors and hybrid vectors containing AAV components are designed to promote stable long-term tial locus in nondividing human cells. An essential question is whether AAV elements function in the context of expression by integration into the host genome of slowly dividing, quiescent or post-mitotic cells. Vectors that an HSV-1 amplicon vector. Amplification of ITR-flanked transgenes from the hybrid amplicon has been demonundergo recombination with the host genome have theoretical drawbacks, such as insertional damage of host strated by rescue experiments, in which the transgene cassette is packaged into AAV virions when cotransgenes, or integration of the transgene into a transcriptionally silent locus. ing an antibiotic selection gene allowed formation of col-
